Scleroderma Lung Study II (SLSII)

Trial Objective

The objective is to determine if a 2-year course of Mycophenolate (CellCept) will be safer and more effective than treatment with a 1-year course of oral Cyclophosphamide (Cytoxan) in patients suffering from active and symptomatic Scleroderma Interstitial Lung Disease.

Patient Groups:
150 patients will be enrolled from 12 sites with 1/2 of the patients receiving CellCept and the other 1/2 receiving Cytoxan.

Study Visits:
Approximately 28 visits over a 2-year period.


Active Clinical Trials Closed to Recruitment

How to Participate

For more information, contact Marianne Morrison, study coordinator, at 303.270.2053 or 303.298.1621 or complete the form below.

Who Can Participate

  • Age 18-75 years old
  • The presence of either limited or diffuse scleroderma
  • Shortness of breath with exertion

Trial Location

Main Campus, Denver, CO


Not Provided

Trial Sponsors

National Heart Blood and Lung Institute(NHLBI)
National Institutes of Health 

Principle Investigators

  • image description
    Kevin Brown, MD

Additional Principle Investigators

Aryeh Fischer, MD